These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 16328407)

  • 21. Acquired cholesteatoma: summary of the cascade of molecular events.
    Louw L
    J Laryngol Otol; 2013 Jun; 127(6):542-9. PubMed ID: 23656971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Alterations of the basal membrane in middle ear cholesteatoma].
    Bernal Sprekelsen M; Ebmeyer J; Anonopoulos A; Borkowski G; Sudhoff H
    Acta Otorrinolaringol Esp; 2001 May; 52(4):330-5. PubMed ID: 11526629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carcinoembryonic antigen in chronic otitis media: an immunohistochemical study of the middle ear mucosa.
    Sankovic S; Sofronic L
    Acta Otorhinolaryngol Belg; 2002; 56(1):61-4. PubMed ID: 11894632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytokines and adhesion molecules in middle ear cholesteatoma. A role in epithelial growth?
    Ottaviani F; Neglia CB; Berti E
    Acta Otolaryngol; 1999; 119(4):462-7. PubMed ID: 10445062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cell cycle inhibitory protein p27 in human middle ear cholesteatoma.
    Kuczkowski J; Bakowska A; Pawelczyk T; Narozny W; Mikaszewski B
    ORL J Otorhinolaryngol Relat Spec; 2006; 68(5):296-301. PubMed ID: 16825801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation of vascular morphology with clinical types in cholesteatoma of the middle ear.
    Stammberger M; Bujía J; Schulz P
    Am J Otol; 1994 May; 15(3):380-2. PubMed ID: 8579144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of disintegrin and metalloproteinase family proteins 10, 12 and 17 in cholesteatoma.
    Erbek S; Erinanc H; Hizal E; Ozluoglu LN
    J Laryngol Otol; 2013 Feb; 127(2):153-8. PubMed ID: 23318052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic value of matrix metalloproteinase 9 and tissue inhibitor of matrix metalloproteinases 1 in cholesteatoma.
    Olszewska E; Matulka M; Mroczko B; Pryczynicz A; Kemona A; Szmitkowski M; Mierzwinski J; Pietrewicz T
    Histol Histopathol; 2016 Mar; 31(3):307-15. PubMed ID: 26490574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aggressiveness and quantification of epithelial proliferation of middle ear cholesteatoma by MIB1.
    Mallet Y; Nouwen J; Lecomte-Houcke M; Desaulty A
    Laryngoscope; 2003 Feb; 113(2):328-31. PubMed ID: 12567091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of NLRP3 inflammasome in human middle ear cholesteatoma and chronic otitis media.
    Kariya S; Okano M; Zhao P; Kataoka Y; Yoshinobu J; Maeda Y; Ishihara H; Higaki T; Nishizaki K
    Acta Otolaryngol; 2016; 136(2):136-40. PubMed ID: 26457439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Expression and significance of HIF-1alpha and iNOS in human middle ear cholesteatoma epithelium].
    Zhang E; Gong S
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2007 May; 21(10):463-5. PubMed ID: 17650819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toll-like receptors 2, 3 and 4 (TLR-2, TLR-3 and TLR-4) are expressed in the microenvironment of human acquired cholesteatoma.
    Szczepański M; Szyfter W; Jenek R; Wróbel M; Lisewska IM; Zeromski J
    Eur Arch Otorhinolaryngol; 2006 Jul; 263(7):603-7. PubMed ID: 16538507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Detection and correlation of lipopolysaccharide, vitamin D receptor and matrix metalloproteinase-9 in the middle ear cholesteatoma].
    Li Y; Xu Z; Zhang L; Quan C; Lin X
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2012 Aug; 26(16):739-41, 746. PubMed ID: 23213753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Current concepts of the pathogenesis of acquired middle ear cholesteatoma].
    Welkoborsky HJ
    Laryngorhinootologie; 2011 Jan; 90(1):38-48; quiz 49-50. PubMed ID: 21225533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidermal growth factor expression in middle ear cholesteatoma.
    Chi HP; Ho KY; Chai CY; Ta CF; Wang LF; Lee KW; Kuo WR; Wu SC; Tsai SM
    Kaohsiung J Med Sci; 2004 Jan; 20(1):6-11. PubMed ID: 15481560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative analysis of the epithelium stroma interaction of acquired middle ear cholesteatoma in children and adults.
    Welkoborsky HJ; Jacob RS; Hinni ML
    Eur Arch Otorhinolaryngol; 2007 Aug; 264(8):841-8. PubMed ID: 17541620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overexpression of placenta growth factor in human middle ear cholesteatoma.
    Cho JG; Lim HW; Woo JS; Hwang SJ; Lee HM; Chae SW
    Acta Otolaryngol; 2006 Sep; 126(9):900-4. PubMed ID: 16864484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Immunological problems in middle ear cholesteatoma].
    Olszewska E; Chodynicki S
    Otolaryngol Pol; 2004; 58(1):85-90. PubMed ID: 15101265
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Galectin-7 as a marker of cholesteatoma residue and its detection during surgery by an immunofluorescent method--a preliminary study.
    Takagi D; Hato N; Okada M; Hakuba N; Gyo K; Shigemoto K; Toda T; Ogasawara M; Kameda K
    Otol Neurotol; 2012 Apr; 33(3):396-9. PubMed ID: 22377647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of secretory leukocyte protease inhibitor in middle ear cholesteatoma.
    Lee JK; Chae SW; Cho JG; Lee HM; Hwang SJ; Jung HH
    Eur Arch Otorhinolaryngol; 2006 Dec; 263(12):1077-81. PubMed ID: 16868773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.